Shift toward early-stage deals favors bioteochs
Article Abstract:
Biotech firms are shifting towards preclincal and early-stage deals to attract pharmaceutical firms, which are favoring such deals in their bid to acquire a potential blockbuster drug at the earliest instance. Phase 1 and preclinical deals doubled their share to about 15% in 2005 from 7% in 2001 as the total value of research partnership between pharmaceutical and biotech firms reached almost $11 billion.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
Public biotech 2006- the numbers
Article Abstract:
The analysis of 419 publicly traded on stock exchanges biotech firms in 2006 reported a great boost in the biotech revenue and expeniture on research but became less profitable.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2007
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Profiles of food & beverage firms. Edelman faces off vs. NHL owners. Profiles of financial PR firms
- Abstracts: Conflicting messages. 2006: Hopes and dangers. Threatening US deficit
- Abstracts: Super Citrimax Wired Energy Drinks. Kizz-Me Energy Drinks
- Abstracts: Granite Gold Penetrating Sealer; Polish/Protector Sprays. Earth Friendly Products Uni Fresh Air Freshner Sprays
- Abstracts: IABC hurt by poor communications. Public sees PR as a sales tool